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A
ntigen-based therapies (ABTs) seek to prevent
or inhibit autoimmune diseases by inducing
regulatory T-cell responses (active tolerance)
or anergizing/deleting pathogenic T-cells (pas-
sive tolerance). The theoretical appeal of this therapeutic
approach is that it may promote tolerance with little
debilitation of the immune system. The clinical application
of ABTs for autoimmune disease is still in its infancy.
Although initial attempts to apply this therapeutic strategy
in multiple sclerosis, rheumatoid arthritis, and type 1
diabetes met with failure, recent results from clinical
studies hold promise that this approach may be able to
delay the onset of type 1 diabetes as well as preserve -cell
function in latent autoimmune diabetes in adults (LADA)
patients and in children newly diagnosed with type 1
diabetes. If veriﬁed, it would be an important translation of
NOD mouse ﬁndings to clinical applications. NOD mouse
studies, however, indicate that the immunological impact
of ABTs is much more dynamic and complex than previ-
ously appreciated. The differences in type 1 diabetes
pathogenesis between rodents and humans, as well as
other immunotherapeutic approaches, have been exten-
sively reviewed elsewhere (e.g., [1–3]). Here, we will focus
on ABTs and discuss what has been learned about their
immunological impact, the theoretical factors affecting
their efﬁcacy and safety, as well as potential markers of
their therapeutic efﬁcacy.
Inﬂammatory T-cell responses spread among -cell
antigens during the development of murine and hu-
man type 1 diabetes. Type 1 diabetes is mediated by
autoreactive T-cells recognizing -cell autoantigens (-
CAAs). In NOD mice, autoreactive CD4
 T-cells are
generally Th1 type (interferon secreting), and autoim-
munity progressively spreads intra- and intermolecularly
among -CAAs such as insulin, GAD, heat shock protein
(HSP), and IGRP during the disease process (4,5). Simi-
larly, spontaneous CD8
 T-cell responses develop to
-CAAs such as insulin, GAD, IGRP, and others (6).
Paralleling observations in NOD mice, autoreactive Th1-
biased CD4
 and CD8
 T-cells arise in human type 1
diabetic patients to many of the same -CAAs (6–9). This
spreading of inﬂammatory T-cell responses creates a
proinﬂammatory cascade, driving disease progression
(10,11).
ABT-induced active tolerance. Autoantigen administra-
tion in modes that induce regulatory T-cell responses such
as Th2 (secreting interleukin [IL]-4 and IL-5), Th3 (secret-
ing TGF), Tr1 (secreting IL-10), and CD4
CD25
Foxp3

Treg (secreting IL-10 and TGF) can inhibit proinﬂamma-
tory Th1 and Th17 responses and prevent disease in
animal models of type 1 diabetes, multiple sclerosis,
rheumatoid arthritis, and uveitis. This induction of active
tolerance does not require information regarding the initi-
ating target antigen or the speciﬁcity of effector T-cells.
When therapy-induced regulatory T-cells encounter the
antigen at sites of inﬂammation, they release anti-inﬂam-
matory cytokines, which locally suppress effector T-cells
regardless of their speciﬁcity in a process termed by-
stander suppression (12). Even though inﬂammatory auto-
reactive T-cell responses persist, ABT-induced regulatory
responses can establish a tissue-speciﬁc long-term func-
tional tolerance without debilitating immune competence.
ABTs not only induce regulatory responses to the ad-
ministered autoantigen, they also promote the spreading
of regulatory responses to other target tissue autoantigens
(13). For example, NOD mice treated with a single -CAA
in incomplete Freund’s adjuvant (IFA, a Th2-promoting
adjuvant) developed Th2 responses to the injected autoan-
tigen as well as all the other tested -CAAs (13,14). This
spreading of regulatory responses is limited to -CAA
target determinants and does not occur in wild-type mice
(13,15). ABT-induced Tr1 and Treg responses have also
been observed to spread in the experimental autoimmune
encephalomyelitis (EAE) model and after organ transplan-
tation (16,17). Thus, like inﬂammatory responses, regula-
tory T-cell responses can spread, presumably through
their secretion of cytokines and their effects on antigen-
presenting cells (APCs) that promote the activation/expan-
sion of similar T-cell responses (13,15,18–20).
This ABT-induced spreading of regulatory responses can
be very broad and rapid. For example, when neonatal NOD
mice were immunized with a single -CAA in IFA, splenic
Th2-type cell autoimmunity arose precociously to every
tested -CAA by the time the mice were 4 weeks old, which
is much sooner than when autoreactivity to these -CAAs
becomes detectable in unmanipulated NOD mice (21). Evi-
dently, prior to the onset of insulitis NOD mice have a broad
array of -CAA–reactive T-cells that can quickly activate
and/or expand when sufﬁcient costimulatory signals are
provided. Because Th2 responses spread to every tested
-CAA target determinant, the number of regulatory T-cell
responses resulting from spreading may far outnumber those
primed to the administered -CAA itself.
Besides increasing bystander suppression, the spread-
ing of regulatory T-cell responses can exhaust naïve
autoantigen-speciﬁc T-cell pools that could be recruited
into the pathogenic response (22). Moreover, their anti-
inﬂammatory cytokines can educate and modulate APCs
into tolerogenic APCs, which can further promote regula-
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DIABETES, VOL. 58, SEPTEMBER 2009 1939tory T-cell responses (18–20). These coinciding effects
may underlie the protective effects of ABT.
Factors affecting the efﬁcacy of ABTs in NOD mice
Size matters. A small antigen may contain only one
determinant that is presented only by a particular major
histocompatability complex, whereas a large protein con-
tains many determinants presented by each major histocom-
patability complex allele product. Accordingly, the size of the
autoantigen used in ABTs affects the magnitude of induced
T-cell responses. Indeed, GAD but not insulin B-chain or
HSPp277 vaccination prolonged syngenic islet graft sur-
vival in diabetic NOD mice (23), and treatment with a
combination of GAD peptides prevented disease more
effectively in NOD mice than the individual peptides (14).
Antigen expression pattern. Each self-protein has a
unique expression pattern leading to differences in central
and peripheral tolerance induction and the number and
avidity of antigen-speciﬁc (cognate) T-cells remaining in
the repertoire (10). In humans, the expression level of
proinsulin in the thymus is regulated by allelic variations
that are linked with type 1 diabetes susceptibility (24). In
NOD mice, proinsulin 2, but not proinsulin 1, is expressed
in the thymus, and knocking out proinsulin 2 expression
accelerates their disease process (25). Whether the GAD65
gene is transcribed in the NOD mouse thymus is contro-
versial, and there is no detectable GAD enzymatic activity
in their thymus (D.L.K., unpublished data). GADs are fairly
rare proteins in neurons, and although GAD65 is ex-
pressed at very low levels in mouse -cells (26), it is
sufﬁcient to allow a GAD65-speciﬁc CD8
 T-cell clone to
rapidly destroy -cells in NOD/scid mice (27). The low
expression of GAD in tissues may underlie the large
high-avidity repertoire of naïve GAD65-reactive T-cells in
preautoimmune NOD mice, which is indicative of little
negative selection (11). The size and avidity of naïve
antigen-speciﬁc T-cell pools determines in large part the
ability of that antigen to prime regulatory responses (28).
Stage of the disease process. Although ABTs can be
highly effective when administered early in the NOD
mouse disease process, they become less effective as the
autoimmune process progresses. The ability of foreign
antigens and non–-cell self-antigens to induce immune
responses in NOD mice is unaffected by their disease
process (Fig. 1A) (22,28). In contrast, there is a dramatic
decline in the ability of whole -CAAs and peptides
containing -CAA target determinants to prime Th2 immu-
nity and Th2 spreading with disease progression (Fig. 1B)
(22,28). This attenuation in the ability of -CAAs to induce
regulatory responses is likely to reﬂect the progressive
recruitment of naïve -CAA–reactive T-cells into the
pathogenic response, which reduces the availability of
naïve cognate T-cells that can be primed by ABT.
After NOD mice develop mild hyperglycemia, ABTs
have little ability to slow disease progression. NOD mice
often progress from mild to severe hyperglycemia within
1–2 weeks, but it takes about 10–14 days for ABTs to
induce maximal immune responses to the administered
-CAA and longer for regulatory T-cell responses to spread
to other -CAAs. By the time ABT-induced regulatory
responses peak, insufﬁcient -cell mass remains. In con-
trast, anti-CD3 and other systemic immunosuppressants
have an immediate effect and can reverse hyperglycemia in
newly diabetic NOD mice (29). Even with anti-CD3 treat-
ment, however, NOD mice must be treated before their
blood glucose exceeds 400 mg/dl to be effective (30). This
suggests that sufﬁcient residual -cell mass is required for
the treatment to be beneﬁcial, a notion supported by
A Control antigens B Target determinants C Ignored determinants
FIG. 1. The ability of target determinants but not ignored determinants to induce Th2 responses attenuates with disease progression in NOD
mice. NOD mice were immunized either at 6 or 12 weeks of age with a peptide containing a control immunogenic foreign (hen egg lysozyme [HEL])
or a self-determinant (mouse serum albumin [MSA]) (A), a major target determinant of a -CAA (B), or an absolute cryptic determinant from
within GAD or from within other -cell antigens that are completely ignored by the autoimmune response (islet amyloid polypeptide [IAPP],
reduced expression in cancer [REC], or calbindin [CALB]) (C) in IFA. Subsequently, the frequency of IL-4–secreting splenic T-cells responding
to the injected antigen was determined by enzyme-linked immunosorbent spot. Data shown is the mean number of IL-4–secreting spot-forming
colonies (SFC). Details about the ignored determinants are provided in (28).
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nation (31,32).
Although ABTs do not efﬁciently reverse hyperglycemia
in NOD mice, ABTs can induce potent regulatory re-
sponses after type 1 diabetes onset, evidenced by the
ability of ABTs to prolong the survival of syngenic islet
grafts in NOD mice (23,33). In these studies, diabetic NOD
mice were given ABT, maintained on insulin, and im-
planted several weeks later with syngenic islets, thereby
allowing sufﬁcient time for the induction of regulatory
responses. Vaccination with GAD, but not insulin B-chain
or HSPp277, prolonged islet graft survival (23). This may
reﬂect GAD’s larger size and numerous immunogenic
determinants as well as greater immunogenicity in NOD
mice with advanced disease (22). Additionally, the size of
the ABT-induced CD4
CD25
 Treg response was an im-
portant factor (33). These ﬁndings suggest that late in the
disease process, regulatory responses may be best elicited
with target tissue antigens that have large pools of uncom-
mitted cognate T-cells available for priming.
Targeted versus ignored -cell antigens. ABTs have
focused on administering the autoantigens themselves.
However, because the ability of -CAAs to prime immune
responses attenuates with disease progression, -cell an-
tigens that are completely uninvolved in the autoimmune
process can, depending on their immunogenicity, prevent
disease more effectively in NOD mice with an advanced
disease process (Figs. 1–3; [28]). Such ABT-induced neo-
A Control antigens B Target determinants C Ignored determinants
FIG. 2. Type 1 diabetes incidence in NOD mice immunized with a control (A), target (B), or ignored (C) antigen. Mice were immunized at 12 weeks
of age with the indicated antigen. *P < 0.05 and **P < 0.01 relative to the unmanipulated NOD mouse group. (Details are provided in ref. 28).
CALB, calbindin; IAPP, islet amyloid polypeptide; MSA, mouse serum albumin; REC, reduced expression in cancer.
FIG. 3. Correlation between a -CAA’s ability to prime responses in NOD mice and its therapeutic efﬁcacy. A: Correlation between a -CAA
ignored determinant’s immunogenicity (as determined in ref. 28) and its therapeutic efﬁcacy (type 1 diabetes incidence at 45 weeks in Fig. 2)
(R  0.87; P  0.02). B: Correlation between the ability of a target or an ignored determinant to prime IL-4–secreting Th2 responses at 12 weeks
of age and its therapeutic efﬁcacy (R  0.86; P  0.002). (Details are provided in ref. 28). SFC, spot-forming colonies; T1D, type 1 diabetes.
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Likewise, the immunogenicity of synthetic peptides con-
taining -CAA target determinants attenuates, but the
immunogenicity of determinants within the same -CAA
that are ignored by the autoimmune process (i.e., absolute
cryptic determinants; Table 1; [34,35]) is unaffected by
disease progression (Fig. 1C; [28]). Because absolute cryp-
tic determinants are poorly presented from whole antigen
and have had little impact on T-cell selection, there are
large pools of cognate T-cells available for priming late in
the disease process by treatment with a synthetic peptide
containing the determinant (which bypasses whole anti-
gen processing) (10,34,35). Vaccination of 12-week-old
NOD mice with absolute cryptic determinants primed
stronger regulatory T-cell responses and prevented type 1
diabetes more effectively than vaccination with the major
target determinants of -CAAs (Figs. 1 and 2). The immu-
nogenicity of targeted and ignored determinants as well as
the magnitude of induced Th2 responses were positively
correlated with their ability to prevent type 1 diabetes in
NOD mice (Fig. 3; [28]). These observations suggest that
fragmenting a large autoantigen (e.g., by endopeptidases
or by using a set of synthetic peptides) may expose many
cryptic determinants and prime more regulatory responses
than whole autoantigen. Inducing regulatory responses to
absolute cryptic -CAA determinants may be safe because
1) regulatory autoreactivity spreads only to -CAA target
determinants, like what occurs after traditional ABTs
(15,28), and 2) it is less likely to boost pathogenic T-cell
responses because cognate T-cells are not already acti-
vated in vivo. In the cancer vaccine ﬁeld, immunization
with cryptic determinants can elicit larger and higher-
avidity T-cell responses than tumor antigen–dominant de-
terminants in mice, and clinical trials using cryptic tumor
antigen determinants are in progress (35,36).
Prior immunological history affects subsequent im-
mune responses. In mice, preexisting Th1 responses can
modify subsequent immune responses to another antigen
administered in a Th2-promoting adjuvant (20). This mod-
ulation may be due to cytokines produced by the ﬁrst wave
of effector and memory cells or by education of APCs
(19,20). Children vaccinated with Bacillus Calmette-
Guerin have reduced incidence of atopic disease, indicat-
ing that an individual’s prior immune responses inﬂuence
subsequent responses (37). Interestingly, GAD/alum vac-
cination (20 g) did not boost GAD autoantibodies in
LADA patients who have a slowly progressing form of type
1 diabetes (Table 1), but greatly increased GAD autoanti-
bodies in newly diabetic children, suggesting that the
aggressiveness of an autoimmune response inﬂuences
immune responses to ABT (see below). If preexisting
autoimmune responses modulate ABT-induced responses,
it may be beneﬁcial to reduce pathogenic responses prior
to ABT, to coadminister factors (e.g., cytokines) that will
help enforce the induction of regulatory responses, and to
optimize ABT dose and frequency for different stages of
the autoimmune process.
ABT dose and route. The subcutaneous administration of
soluble self-antigen is generally only weakly immunogenic,
but repeated treatments can prime regulatory responses
(38,39). Mucosal delivery favors the generation of regulatory
responses (12,40). Inhalation of antigen induces regulatory
T-cell responses more effectively than delivering the antigen
orally. The most efﬁcient way to induce robust responses to
self-antigens is to deliver them in adjuvants. Immunization
with adjuvant provides a depot of antigen that can promote
tolerogenic T-cells and APCs long-term in vivo. However, a
more robust immune response has the inherent danger of
inducing more undesired responses.
DNA vectors that express a -CAA are stable and can
codeliver other genes encoding immune-modulating pro-
teins. Since CpG motifs in DNA act as proinﬂammatory
adjuvants by binding to a Toll-like receptor, codelivery of
immunoregulatory genes may be necessary to drive func-
tionally dominant regulatory responses (e.g., [33]).
The effect of ABT dose and frequency in humans with
ongoing autoimmunity is only beginning to be studied and
remains a key issue for developing ABTs. We should
presume that ABTs will evoke a mixture of immune
responses including inducing regulatory T-cells, boosting
pathogenic responses, and causing T-cell exhaustion, an-
ergy, and deletion. The extent of each of these responses
may depend on the dose, route, and frequency of treat-
ment. Such mixed responses to ABT may explain why
different dosages of oral insulin gave variable results in a
small clinical trial with new-onset type 1 diabetic patients
(41), why the beneﬁcial effect of GAD/alum vaccination in
LADA patients was conﬁned to a particular dose and did
not display dose dependency (42), and why GAD/alum-
treated new-onset type 1 diabetic patients displayed a very
TABLE 1
Glossary
Active tolerance Active tolerance is based on the induction of immune responses that can suppress pathogenic
responses, achieving a functional tolerance.
Passive tolerance Passive tolerance is based on deleting/anergizing autoantigen-speciﬁc T-cells.
Determinant A short continuous amino acid stretch within a peptide that binds to MHC class I or II, which is
recognized by T-cell receptors. In contrast, an epitope comprises continuous or noncontinuous parts
of a macromolecule and is recognized by an antibody.
Dominant determinant Dominant determinants are efﬁciently processed from whole antigens and presented by MHC.
Cryptic determinant These are immunogenic determinants that are poorly processed and presented from whole antigen but
can elicit immune responses when delivered in synthetic peptides (which bypasses whole-antigen
processing). Cryptic determinants often become targets of autoimmune responses because their
presentation becomes sufﬁcient to activate cognate T-cells in the context of inﬂammation (ref. 34).
Other cryptic determinants are immunogenic but never become involved in the autoimmune
response and are termed absolute cryptic determinants (ref. 35). Because these determinants have
had little impact on T-cell selection, there are large pools of cognate T-cells available for priming by
ABT (ref. 28).
LADA LADA describes adults with a slowly progressive form of type 1 diabetes. The diagnosis of LADA is
based on 1) adult onset of diabetes, 2) circulating islet autoantibodies, and 3) insulin independence
at diagnosis. About 10% of adults with non–insulin-requiring diabetes have LADA.
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Passive tolerance. ABTs can induce passive tolerance
by anergizing/deleting autoreactive T-cells. Passive toler-
ance can also be created in transgenic animals by sup-
pressing autoantigen expression or by eliminating target
determinants from an autoantigen. Passive tolerance to
insulin (43,44) and GAD (4,45) in NOD mice prevents the
development of insulitis and type 1 diabetes. These ob-
servations may deﬁne primary -cell autoantigen(s) or
point to autoreactivities that are necessary drivers of the
autoimmune response without which other nascent auto-
reactivities succumb to activation-induced cell death or
regulation. Transgenic NOD mice that are largely, but
incompletely, passively tolerized to GAD (46) initially have
a broad reduction in T-cell responses to other -CAAs,
indicating that early T-cell autoreactivities require mutual
support for expansion (J.T., D.L.K., unpublished data). As
the mice grow older, however, they develop supernormal
T-cell responses to other -CAAs, such that disease inci-
dence is unabated. Thus, deleting/anergizing many GAD-
reactive T-cells allowed other -CAA–reactive T-cells to
eventually expand to a greater extent, perhaps by reducing
competition for APCs or homeostatic proliferation in the
target tissue. These ﬁndings underscore the dynamic na-
ture of autoimmune responses after altering the T-cell
repertoire to a single self-antigen and the potential for
unexpected consequences.
It is unknown whether an initiating antigen exits in
human type 1 diabetes. Central and peripheral tolerance
induction mechanisms should only leave T-cells that inter-
act with -CAAs at subactivation thresholds. Theoreti-
cally, when a perturbation in antigen presentation arises
from islet remodeling, metabolic demands, or local inﬂam-
mation, T-cells (reactive to multiple -CAAs) that were
previously interacting with cognate -CAAs at just below
activation thresholds should receive sufﬁcient stimulation
to activate and expand, causing multiple initial beaks in
self-tolerance. In this case, enforcing passive tolerance to
a single -CAA in preautoimmune humans may have little
beneﬁt, unless there are key driver T-cell autoreactivities.
The administration of self-antigens intravenously in the
absence of sufﬁcient costimulatory signals is a classic
modality to induce passive tolerance. However, continued
antigen treatments may be necessary to enforce passive
tolerance because new naive T-cells will emerge from the
thymus. Moreover, the induction of passive tolerance to
single autoantigen after the onset of autoimmunity is unlikely
to be effective because T-cell reactivities to other -CAAs can
drive disease progression. Accordingly, after the onset of
autoimmunity, the induction of long-lived regulatory re-
sponses is, theoretically, a better therapeutic strategy.
Prevention trials of antigen-based therapies for
those at risk for type 1 diabetes. The Diabetes Preven-
tion Trial (DPT)-1 tested whether daily subcutaneous
insulin injections and annual intravenous insulin infusions
could prevent disease in individuals at high risk for
developing type 1 diabetes. This treatment was geared to
induce -cell rest, but immunological mechanisms might
also be evoked because insulin treatment can boost insulin
autoantibodies and induce Th2 responses (39). The DPT-1
found no effect on type 1 diabetes incidence (47). Because
the treatment did not alter the subject’s insulin autoanti-
body (IAA) levels, its immunological impact has been
questioned. Another arm of the DPT-1 found that oral
insulin treatment had no overall effect (48) but did delay
type 1 diabetes onset in a subpopulation with high IAA
(49). Understanding the beneﬁcial effect of treatment in
this subpopulation may help in designing more efﬁcacious
ABTs. Reasons for the overall lack of efﬁcacy could
include suboptimal dose, degradation of the immunogen,
weak immunogenicity via this route, and simultaneous
induction of regulatory and pathogenic responses.
The Type 1 Diabetes Prediction and Prevention Study
concluded that daily intranasal insulin treatment could not
prevent or delay diabetes, even when treatment began
soon after autoantibodies arose (50). There were no
changes in -cell–reactive antibodies associated with
treatment. In contrast, the Intranasal Insulin Trial showed
that intranasal insulin administration to individuals at high
risk for developing type 1 diabetes increased antibodies
and decreased T-cell responses to insulin, and a subsequent
clinical trial is in progress (40). Together, these initial pre-
vention studies have been reassuring in terms of safety, but
have raised questions about immunological impact, optimal
mode of antigen delivery, and antigen dose.
Intervention trials of ABTs in recent-onset type 1
diabetic patients. Disease prevention is preferable to inter-
vention after disease onset, but requires screening individu-
als for type 1 diabetes risk markers and runs the risk of
exacerbating the disease process. Intervention trials are
more affordable because potential subjects are readily iden-
tiﬁed and efﬁcacy can be evaluated within a shorter time
frame. Preserving residual -cell function after type 1 diabe-
tes onset may prevent or delay long-term complications.
Insulin-based intervention trials. There have been four
clinical trials of oral insulin and one trial of an altered
insulin B-chain peptide (NBI-6024, subcutaneous) in newly
diabetic individuals (41,51–53). Most have observed no
protective effect on residual -cell function and no study-
related change in autoantibodies to -CAAs (51–53). One
study observed a slower decline in plasma C-peptide levels
in a subpopulation of patients (41). However, two studies
found tendencies for basal C-peptide to decline faster in an
oral insulin–treated subgroup (41,52), raising concern that
treatment could in some cases accelerate the disease
process. In other studies, intradermal treatment with a low
dose (30 g), but not a high dose (300 g), of a soluble
DR4-restricted proinsulin peptide induced transient IL-10–
secreting T-cell responses in patients with long-standing
type 1 diabetes (54).
Intervention trials using HSPp277. There have been
several small clinical trials of vaccination with an altered
HSPp277 peptide in an adjuvant (Diapep), which induces
IL-10– (predominantly), IL-4–, and IL-13 antigen–speciﬁc
responses (rev. in [55]). Most of these studies have re-
ported a beneﬁcial effect. Individuals with higher IL-10
before treatment responded better to treatment. Parallel-
ing this ﬁnding, another study found that new-onset type 1
diabetic patients with more IL-10 production are more
likely to experience a honeymoon phase (56). These
observations suggest that the individual’s predispositions
to develop regulatory responses and/or preexisting im-
mune responses may inﬂuence ABT-induced responses.
GAD/alum vaccine in LADA and new-onset type 1
diabetes. Clinical trials of GAD/alum vaccination were
ﬁrst conducted in individuals with LADA, a slowly pro-
gressing form of type 1 diabetes (Table 1) (42). Subjects
received placebo or GAD/alum (4, 20, 100, or 500 g)
subcutaneously, twice. Only the 500-g dose boosted GAD
autoantibody levels. After 6 months, the CD4
CD25
/
CD4
CD25
 cell ratio, as well as serum C-peptide levels,
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Evidently, ABT can have a beneﬁcial immunomodulatory
effect without changing humoral responses to the admin-
istered antigen, at least in LADA patients. A 5-year fol-
low-up reported no signiﬁcant study-related adverse
effects and that C-peptide levels were signiﬁcantly higher
only in the 20-g–dose group (57). If conﬁrmed, this
treatment may provide a safe long-term therapy to pre-
serve -cell function in LADA patients.
The mechanisms underlying the apparent effectiveness
of the 20-g dose, but not other dosages, are not yet
evident. Multiple low doses of antigen often induce toler-
ance by priming regulatory responses. High antigen/adju-
vant dosages often induce tolerance by exhausting
antigen-speciﬁc T-cells but can promote humoral re-
sponses because some antigen escapes from the adjuvant
and can directly activate memory B-cells, which may
explain why the high GAD/alum dose was ineffective but
boosted GAD autoantibodies. Alternatively, each GAD/
alum dose may have evoked a different mixture of immune
responses (i.e., regulatory responses, boosting of patho-
genic responses, exhaustion, anergy, and deletion). The
20-g dose may have induced the most favorable ratio of
beneﬁcial/pathogenic responses to promote functional tol-
erance. The notion that treatment induced a mixture of
immune responses is supported by observations that com-
pared with PBMCs from placebo-treated controls, PBMCs
from GAD/alum-treated type 1 diabetic subjects secreted
higher levels of a diverse array of cytokines in response to
GAD (see below).
The beneﬁcial effect of the 20-g GAD/alum dose was
further supported by a subsequent larger clinical trial with
newly diabetic children (32). This study found that GAD/
alum (20 g) vaccination preserved -cell function in
patients treated within 6 months of type 1 diabetes onset
but not in those treated 6 months after type 1 diabetes
onset. The effectiveness of treatment in more recently
diagnosed patients is likely to reﬂect greater remaining
-cell mass. This parallels ﬁndings with anti-CD3 treat-
ment in which the treatment was most effective in those
with the highest residual -cell function at the time of
treatment (31). The treatment induced higher levels of
IL-5, IL-10, and IL-13 GAD-speciﬁc responses accompanied
by higher frequency of Foxp3
 and TGF-secreting T-
cells, even after 15 months (32). Interestingly, treatment
also promoted higher levels of some proinﬂammatory
cytokine responses to GAD. It is possible that these
proinﬂammatory factors were counteracted by the en-
hanced regulatory responses or that these factors partici-
pated in regulatory circuits. In contrast to the LADA study,
GAD/alum treatment greatly boosted GAD autoantibodies
in new-onset type 1 diabetic patients, indicating a differ-
ence in immune responses to GAD/alum vaccination de-
pending on whether the individual had a slow or more
aggressive disease process. Further analysis revealed that
the best responders to GAD/alum were individuals with
higher initial levels of GAD autoantibody (58), an obser-
vation reminiscent of oral insulin’s beneﬁcial effects in
individuals with high IAA at entry into the DPT-1 (49).
In this study, the major factor affecting a subject’s
responsiveness to therapy was time to treatment, suggest-
ing that residual -cell mass at the time of treatment is a
major factor inﬂuencing GAD/alum effectiveness. In this
regard, it is notable that LADA patients, who are likely to
have more -cell mass than new-onset type 1 diabetic
patients (i.e., they are not yet insulin dependent), actually
increased their C-peptide secretion over baseline 1 year
after 20-g GAD/alum treatment (42). Importantly, al-
though insulin secretion gradually decreased in GAD/
alum-treated new-onset type 1 diabetic patients, the rate
of decline was similar to that reported after anti-CD3
treatment (31,32,59). However, GAD/alum therapy did not
have signiﬁcant adverse side effects. This, together with
the relative stability of GAD/alum preparations, may make
this treatment well suited for use in developing countries.
The safety of ABTs. There is abundant evidence from
animal models that ABTs can have potentially deleterious
effects. For example, when neonatal NOD mice are vacci-
nated with any -CAA in IFA, they develop precocious Th2
(predominantly) and some Th1 responses to the adminis-
tered -CAA by 4 weeks of age (21). Thus, despite treating
NOD mice well before the onset of insulitis and using a
Th2-promoting adjuvant, ABT promoted some Th1 re-
sponses to the injected -CAA. Apparently, partially or
fully activated Th1 cells reactive to many different -CAAs
are already present in NOD mice well before the develop-
ment of insulitis, which can rapidly expand to detectable
levels in the context of increased autoantigen stimulation
(21). Additionally, oral insulin exacerbated disease in BB
rats, insulin B(9–23)/IFA boosted cognate Th1 responses
in older NOD mice, mucosal autoantigen delivery can
prime pathogenic CD8
 T-cell responses (40), repeated
administration of -CAA peptides can induce anaphylaxis,
Th2 cells can induce disease in immunodeﬁcient mice, and
induced autoimmunity to HSPs can lead to destruction of
retinal cells in rats. Finally, GAD autoimmunity is often
found in individuals with a rare neurological disorder
called stiff-person’s syndrome and sometimes in other rare
neurodegenerative diseases, raising concerns that ABTs
that boost GAD autoimmunity could have deleterious
neurological consequences.
In type 1 diabetes clinical trials thus far, there is some
indication that oral insulin can accelerate the reduction in
C-peptide levels in some new-onset type 1 diabetic patient
subgroups (41,52) and that depending on the dose, oral
insulin may be beneﬁcial or deleterious (41). Although the
lack of ABT beneﬁcial effects in most type 1 diabetes
clinical trials has been ascribed to an insufﬁcient immuno-
logical impact, it could also reﬂect ABTs inducing both
beneﬁcial and pathogenic responses that counteracted one
another. Due to the potential to accelerate -cell damage,
ABT trials should ﬁrst be tested for their ability to preserve
residual -cell mass in new-onset type 1 diabetic patients
and assessed for their long-term safety before extending
the treatment to the pre-diabetic population.
Markers of therapeutic efﬁcacy. Studies of ABTs in
NOD mice, as well as studies of cancer vaccines in
humans, have found that the magnitude of the antigen-
induced immune response and the extent of determinant
spreading of T-cell responses to other target tissue anti-
gens are associated with better clinical outcomes (28,60).
Currently, there are no surrogate immunological markers
of ABT efﬁcacy in humans. These are urgently needed to
quickly assess candidate treatments rather than relying on
the long-term clinical outcome. Although induction anti-
gen–speciﬁc IgG1 is associated with the induction of
regulatory Th2 responses in mice (e.g., [23]), such autoan-
tibody isotype associations are not clear in humans. More-
over, humoral responses may not be associated with
therapeutic efﬁcacy, as observed in GAD/alum-treated
LADA patients (42).
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T-cell responses in humans currently requires multiple labor-
intensive assays. Autoantigen-speciﬁc T-cells are present in
blood at very low frequency, such that the development of
assays that can reproducibly measure T-cell responses to
multiple -CAAs simultaneously at the single T-cell level will
be valuable. These assays, together with the measurement of
different subclasses of -CAA–speciﬁc antibodies, may allow
assessments of the efﬁcacy of ABTs in clinical trials. In
addition, imaging technologies such as magnetic resonance
imaging and positron emission tomography have growing
potential to noninvasively image islet inﬂammation and -cell
mass in humans, but are costly.
Future prospects. ABTs have the advantage of being less
immune invasive than immunosuppressive therapies and
are relatively easy and inexpensive to manufacture, admin-
ister, and store. ABT clinical trials are largely focused on
intervention after type 1 diabetes onset as a test platform.
However, no ABT or systemic immune–modulating clini-
cal intervention trial has achieved long-term euglycemia.
Accordingly, there is great interest in combination thera-
pies that combine an immune modulator (antigen speciﬁc
or systemic immunosuppressant) with a factor that pro-
motes -cell regeneration. However, these treatments may
need repeating, and permanent remission may be hard to
safely establish in the context of established autoimmunity
and greatly diminished -cell mass.
Long-term goals should be ﬁxed on preventing type 1
diabetes for multiple reasons: 1) there are excellent ge-
netic and autoantibody markers of susceptibility, and type
1 diabetes has a long prodomal phase; 2) less invasive
treatments may be efﬁcacious at earlier stages of the
disease process; 3) prevention costs may be less than
those of insulin therapy and treating long-term complica-
tions. An ABT that bolsters regulatory responses to
-CAAs long-term in at-risk individuals appears to be the
most promising and safe monotherapy. As preventive
therapies become available, it will be important to have
inexpensive high-throughput screening methods to iden-
tify those at risk for type 1 diabetes. Development of a
blood spot collection card that can be mailed for autoan-
tibody detection may enable cost-effective surveillance
and disease prevention.
Areas of research that might yield insights for optimiz-
ing ABTs are presented in Table 2. The success of some
ABTs in phase II clinical trials engenders cautious opti-
mism that new treatments will enable the prevention of
type 1 diabetes and help preserve -cell function after type
1 diabetes onset.
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